D-Allulose Attenuates High-Fat Diet-Induced NAFLD in Mice by Reducing Lipid Accumulation and Inflammation

Why this paper matters

If you formulate reduced-sugar foods, you know allulose as a bulk sweetener. This paper gives you another reason to watch it. A team published findings in Frontiers in Nutrition (DOI: 10.3389/fnut.2025.1574151) on D-allulose in a mouse model of nonalcoholic fatty liver disease (NAFLD). D-allulose reduced liver lipid accumulation and inflammatory damage. It did not just replace sugar. It changed how the liver handled a high-fat diet.

NAFLD follows metabolic overload. It tracks obesity, dyslipidemia, and poor glucose control. Consumers want better-for-you foods. Allulose fits that story. It delivers sweetness with only 0.3% of sucrose’s energy. That number alone is compelling. But the new evidence adds more.

Background

Allulose is a rare sugar. The paper positions it as an ideal sucrose substitute. It also has anti-inflammatory properties and suppresses lipid synthesis. In this NAFLD model, those effects showed up in the liver and beyond.

What the study did

The paper used a high-fat diet to induce NAFLD in mice and looked at D-allulose treatment. The evidence covers:

• hepatic lipid accumulation
• inflammatory injury
• serum lipid profile
• oxidative stress status
• gut microbiota composition
• serum metabolome balance

Key findings

The results are consistent. D-allulose made the NAFLD phenotype less severe.

Measure	Effect observed with D-allulose
Liver lipid accumulation	Reduced
Liver inflammatory injury	Reduced
Serum lipid profile	Improved
Oxidative stress status	Improved
Gut microbiota composition	Beneficial bacteria, including Akkermansia, increased
Serum metabolome balance	Restored toward normal

The Akkermansia increase matters. Akkermansia often drops in obesity and metabolic disease. Here, D-allulose shifted the microbiota in a favorable direction. The serum metabolome data show the effect spreads beyond the liver.

The energy math matters too. At 0.3% of sucrose’s calories, allulose changes energy density when it replaces sugar. But the anti-inflammatory and anti-lipogenic effects are not just calorie effects.

What it means for manufacturers

Buyers often compare allulose to other sweeteners on sweetness cost. That comparison misses the point. If allulose carries metabolic activity, the cost conversation changes.

Don’t put NAFLD claims on a label yet. This is mouse work. Human trials will decide what claims are possible. But when you evaluate suppliers, ask about their human research roadmap. Allulose may soon be more than a sugar swap.

FAQ

Does this prove allulose treats NAFLD in humans? No. This is an animal model. Human studies are required before any health claim.

What dose did the mice receive? The evidence here doesn’t include dose. Check the full paper for the feeding protocol.

Is allulose just a sweetener? The paper positions it as an ideal sucrose substitute. It also has anti-inflammatory activity and suppresses lipid synthesis. So no, it behaves like a metabolically active ingredient.

The next step

This paper gives formulators a reason to think about allulose beyond sweetness. It reduces liver fat, calms inflammation, and shifts gut bacteria in a beneficial direction. The evidence is from mice. The next step is human data. Ingredient buyers should watch that space closely.